Syncona Limited (SYNC) has announced that its portfolio company, Mosaic Therapeutics, has in-licensed two clinical-stage assets from Astex Pharmaceuticals, a subsidiary of Otsuka Pharmaceutical Co., Ltd. The deal marks a significant step forward for Mosaic’s targeted oncology strategy and is expected to accelerate the company’s development timeline. The agreement grants Mosaic exclusive rights to develop … Continue reading Syncona’s Mosaic Therapeutics secures clinical-stage assets from Astex Pharmaceuticals